Published in Hepatitis Weekly, September 3rd, 2001
Although HAV vaccination is suggested for patients who have liver disease in order to avoid the increased risk of death or illness that could result from HAV infection, few studies have investigated the efficacy of vaccination in advanced, chronic liver disease sufferers, leaving doctors with very little information about immunological responsiveness in those patients,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.